Should You Buy Assertio Holdings Inc (ASRT) Stock After it Is Up 14.61% in a Week?

Assertio Holdings Inc (ASRT) stock has gained 14.61% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Assertio Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ASRT!

See Full ASRT Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With ASRT Stock Today?

Assertio Holdings Inc (ASRT) stock is trading at $1.02 as of 12:33 PM on Tuesday, Mar 12, a rise of $0.09, or 9.28% from the previous closing price of $0.93. The stock has traded between $0.98 and $1.21 so far today. Volume today is high. So far 4,014,111 shares have traded compared to average volume of 672,831 shares.

More About Assertio Holdings Inc

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. Click Here to get the full Stock Report for Assertio Holdings Inc stock.